Company intelligence / Profile preview

Yumanity Therapeutics

Boston, Massachusetts, United Statesmarketscreener.com ↗

Ownership: Private
Development stage: Phase 1

Overview

YTX-7739, the lead product candidate for Parkinson's disease, completed Phase 1b clinical trials with positive results in 2021. The drug was generally well tolerated with favorable pharmacokinetic/pharmacodynamic profiles, demonstrated target engagement, and showed no serious adverse events. The company planned to advance to Phase 2 in 2022, but later underwent restructuring and strategic alternatives exploration.

Therapeutic areas: OncologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

YTX-7739

Phase 1

Indications: Parkinson's disease

Partnerships

Merck & Co.Johnson & Johnson (Janssen)

Beyond the preview

Go deeper on Yumanity Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yumanity Therapeutics.

Explore the full profile